The global myasthenia gravis drugs market is expected to grow at a CAGR of 5.5% during the forecast period, to reach USD 1.2 billion by 2030. The growth of this market is driven by the increasing prevalence of myasthenia gravis and the introduction of new drugs in the market. Anticholinesterases are expected to be the fastest-growing segment in this market, with a CAGR of 6.8%. This growth can be attributed to their efficacy and safety profile as well as their low cost per dose, which makes them an attractive option for patients with mild or moderate symptoms who do not require immunosuppressants or intravenous immune globulins (IVIG). Anticholinesterases are also used for treating other conditions such as Alzheimer's disease and Parkinson's disease, which will drive their demand over the next few years. North America is expected to dominate this market during the forecast period due to its high prevalence rate and availability of advanced healthcare facilities that offer treatment options for myasthenia gravis patients such as IVIGs and immunosuppressants that are not available in other regions such as Latin America, Europe, Asia Pacific, Middle East & Africa (MEA).
Some Of The Growth Factors Of This Market:
- Increasing prevalence of autoimmune disorders, such as myasthenia gravis, is one of the major factors driving the growth of this market.
- Increasing number of clinical trials for new drugs in this segment is also expected to fuel the growth of this market during the forecast period.
- Growing geriatric population and increasing incidence rates are some other factors that are expected to drive the growth of this market during the forecast period.
- Lack of awareness about myasthenia gravis and its treatment options among patients and healthcare providers is one factor that may hinder the growth rate in near future.
Industry Growth Insights published a new data on “Myasthenia Gravis Drugs Market”. The research report is titled “Myasthenia Gravis Drugs Market research by Types (Anticholinesterases, Immunosuppressants, Intravenous Immune Globulins), By Applications (Hospitals, Clinics), By Players/Companies Flamel Technologies, Roche, Grifols, Pfizer, Shire, Novartis, Valeant, Alexion, Catalyst, CSL, Curavac, Cytokinetics, Galencia, GlaxoSmithKline, Lupin Pharmaceuticals, Mitsubishi Tanabe Pharma”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Myasthenia Gravis Drugs Market Research Report
By Type
Anticholinesterases, Immunosuppressants, Intravenous Immune Globulins
By Application
Hospitals, Clinics
By Companies
Flamel Technologies, Roche, Grifols, Pfizer, Shire, Novartis, Valeant, Alexion, Catalyst, CSL, Curavac, Cytokinetics, Galencia, GlaxoSmithKline, Lupin Pharmaceuticals, Mitsubishi Tanabe Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
241
Number of Tables & Figures
169
Customization Available
Yes, the report can be customized as per your need.
Global Myasthenia Gravis Drugs Market Report Segments:
The global Myasthenia Gravis Drugs market is segmented on the basis of:
Types
Anticholinesterases, Immunosuppressants, Intravenous Immune Globulins
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Flamel Technologies
- Roche
- Grifols
- Pfizer
- Shire
- Novartis
- Valeant
- Alexion
- Catalyst
- CSL
- Curavac
- Cytokinetics
- Galencia
- GlaxoSmithKline
- Lupin Pharmaceuticals
- Mitsubishi Tanabe Pharma
Highlights of The Myasthenia Gravis Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Anticholinesterases
- Immunosuppressants
- Intravenous Immune Globulins
- By Application:
- Hospitals
- Clinics
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Myasthenia Gravis Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Myasthenia gravis (MG) is a neuromuscular disorder that affects the ability of the muscles to contract. MG can be caused by a number of factors, including an autoimmune response or viral infection. Drugs used to treat MG include acetylcholinesterase inhibitors (AChEIs), which block the action of acetylcholine, and muscle relaxants.
Some of the major players in the myasthenia gravis drugs market are Flamel Technologies, Roche, Grifols, Pfizer, Shire, Novartis, Valeant, Alexion, Catalyst, CSL, Curavac, Cytokinetics, Galencia, GlaxoSmithKline, Lupin Pharmaceuticals, Mitsubishi Tanabe Pharma.
The myasthenia gravis drugs market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Myasthenia Gravis Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Myasthenia Gravis Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Myasthenia Gravis Drugs Market - Supply Chain
4.5. Global Myasthenia Gravis Drugs Market Forecast
4.5.1. Myasthenia Gravis Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Myasthenia Gravis Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Myasthenia Gravis Drugs Market Absolute $ Opportunity
5. Global Myasthenia Gravis Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Myasthenia Gravis Drugs Market Size and Volume Forecast by Type
5.3.1. Anticholinesterases
5.3.2. Immunosuppressants
5.3.3. Intravenous Immune Globulins
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Myasthenia Gravis Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Myasthenia Gravis Drugs Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Clinics
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Myasthenia Gravis Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Myasthenia Gravis Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Myasthenia Gravis Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Myasthenia Gravis Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Myasthenia Gravis Drugs Demand Share Forecast, 2019-2026
9. North America Myasthenia Gravis Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Myasthenia Gravis Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Myasthenia Gravis Drugs Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Clinics
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Myasthenia Gravis Drugs Market Size and Volume Forecast by Type
9.7.1. Anticholinesterases
9.7.2. Immunosuppressants
9.7.3. Intravenous Immune Globulins
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Myasthenia Gravis Drugs Demand Share Forecast, 2019-2026
10. Latin America Myasthenia Gravis Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Myasthenia Gravis Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Myasthenia Gravis Drugs Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Clinics
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Myasthenia Gravis Drugs Market Size and Volume Forecast by Type
10.7.1. Anticholinesterases
10.7.2. Immunosuppressants
10.7.3. Intravenous Immune Globulins
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Myasthenia Gravis Drugs Demand Share Forecast, 2019-2026
11. Europe Myasthenia Gravis Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Myasthenia Gravis Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Myasthenia Gravis Drugs Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Clinics
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Myasthenia Gravis Drugs Market Size and Volume Forecast by Type
11.7.1. Anticholinesterases
11.7.2. Immunosuppressants
11.7.3. Intravenous Immune Globulins
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Myasthenia Gravis Drugs Demand Share, 2019-2026
12. Asia Pacific Myasthenia Gravis Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Myasthenia Gravis Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Myasthenia Gravis Drugs Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Clinics
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Myasthenia Gravis Drugs Market Size and Volume Forecast by Type
12.7.1. Anticholinesterases
12.7.2. Immunosuppressants
12.7.3. Intravenous Immune Globulins
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Myasthenia Gravis Drugs Demand Share, 2019-2026
13. Middle East & Africa Myasthenia Gravis Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Myasthenia Gravis Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Myasthenia Gravis Drugs Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Clinics
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Myasthenia Gravis Drugs Market Size and Volume Forecast by Type
13.7.1. Anticholinesterases
13.7.2. Immunosuppressants
13.7.3. Intravenous Immune Globulins
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Myasthenia Gravis Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Myasthenia Gravis Drugs Market: Market Share Analysis
14.2. Myasthenia Gravis Drugs Distributors and Customers
14.3. Myasthenia Gravis Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Flamel Technologies
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Roche
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Grifols
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Pfizer
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Shire
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Novartis
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Valeant
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Alexion
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Catalyst
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. CSL
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Curavac
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Cytokinetics
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Galencia
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. GlaxoSmithKline
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Lupin Pharmaceuticals
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Mitsubishi Tanabe Pharma
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook